2017
Locally advanced breast cancer in elderly patients
HORNOVA, Jana, Zbyněk BORTLÍČEK, Petra MÁJKOVÁ, Jitka ABRAHAMOVA, Drahomira KORDIKOVA et. al.Základní údaje
Originální název
Locally advanced breast cancer in elderly patients
Autoři
HORNOVA, Jana (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Petra MÁJKOVÁ (203 Česká republika, domácí), Jitka ABRAHAMOVA (203 Česká republika), Drahomira KORDIKOVA (203 Česká republika), Zuzana DONATOVA (203 Česká republika), Martin KUPEC (203 Česká republika), Ludmila BOUBLIKOVA (203 Česká republika), Josef DVORAK (203 Česká republika), Radek ZAPLETAL (203 Česká republika) a Tomas BUCHLER (203 Česká republika)
Vydání
Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic, Olomouc, Palacký University, 2017, 1213-8118
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.087
Kód RIV
RIV/00216224:14110/17:00097429
Organizační jednotka
Lékařská fakulta
UT WoS
000406522700014
Klíčová slova anglicky
breast cancer; Charlson score; elderly; retrospective analysis; survival
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 20. 3. 2018 14:04, Soňa Böhmová
Anotace
V originále
Background. Although locally advanced breast cancer (LABC) is more common in the elderly population, there is little data on the clinical characteristics and survival of these patients. The aim of the present study was to compare different factors affecting survival in elderly patients with LABC. Methods. Retrospective analysis was carried out on a cohort of 80 patients aged 70 to 96 years, diagnosed with LABC defined as T3 N1, T4 N0, any N2 or N3, and M0. The prognostic impact of selected clinical parameters including age, comorbidities, tumour grade, HER2 status, tumour stage, local therapies, and systemic treatments was studied. Results. The median age of the patients was 79 years. The majority (n=53; 66%) had at least one significant comorbidity according to the Charlson score evaluation. The median overall survival was 50.6 months. As expected, hormonal therapy was the dominant mode of systemic treatment, but 24% also received at least one line of chemotherapy. Local therapies including surgery and/or radiotherapy were applied in 58% of patients. Conclusions. The diagnosis of LABC in the elderly is associated with poor prognosis. Age and serious comorbidities were negative prognostic factors.